Tumor Antigen-sensitized DC Vaccine As an Adjuvant Therapy for Esophagus Cancer
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-sensitized DC vaccine in postoperative adjuvant treatment of esophageal cancer.
Carcinoma|Esophagus Cancer
BIOLOGICAL: Tumor antigen-sensitized DC vaccine
Number of participants with treatment-related adverse events as events as assessed by CTCAE v4.0, Number of participants with treatment-related adverse events as events as assessed by CTCAE v4.0, 3 months after the last administration of cells
Disease-free Survival, Number of participants with Disease-free Survival as assessed by RECIST1.1, through study completion, an average of 1 year
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-sensitized DC vaccine in postoperative adjuvant treatment of esophageal cancer.